Cystic fibrosis

Update on treatment guidelines and new recommendations

Edward M. DeSimone, Jennifer Tilleman, Martin E. Giles, Boussina Moussa

Research output: Contribution to specialist publicationArticle

Abstract

Cystic fibrosis (CF) is a genetic disorder that affects various body systems, leading to premature death. Newborn screening in all states has helped identify those who have this disorder and allows for earlier interventions. Although traditionally viewed as a pulmonary disorder, treatments are available to address the various manifestations of CF. Airway clearance, nutritional support, pancreatic-enzyme replacement, and chronic antibiotic therapy are among the current recommended treatments. The most recent development involves the use of cystic fibrosis transmembrane conductance regulators that help to correct the underlying problem rather than just treat the symptoms. Pharmacists can serve an important role in the proper treatment of primary and secondary symptoms of CF.

Original languageEnglish (US)
Pages16-21
Number of pages6
Volume43
No5
Specialist publicationU.S. Pharmacist
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Bridge clearances
Cystic Fibrosis Transmembrane Conductance Regulator
Cystic Fibrosis
Screening
Guidelines
Anti-Bacterial Agents
Enzymes
Inborn Genetic Diseases
Premature Mortality
Nutritional Support
Therapeutics
Pharmacists
Newborn Infant
Lung

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Cite this

DeSimone, E. M., Tilleman, J., Giles, M. E., & Moussa, B. (2018). Cystic fibrosis: Update on treatment guidelines and new recommendations. U.S. Pharmacist, 43(5), 16-21.

Cystic fibrosis : Update on treatment guidelines and new recommendations. / DeSimone, Edward M.; Tilleman, Jennifer; Giles, Martin E.; Moussa, Boussina.

In: U.S. Pharmacist, Vol. 43, No. 5, 01.05.2018, p. 16-21.

Research output: Contribution to specialist publicationArticle

DeSimone, EM, Tilleman, J, Giles, ME & Moussa, B 2018, 'Cystic fibrosis: Update on treatment guidelines and new recommendations' U.S. Pharmacist, vol. 43, no. 5, pp. 16-21.
DeSimone, Edward M. ; Tilleman, Jennifer ; Giles, Martin E. ; Moussa, Boussina. / Cystic fibrosis : Update on treatment guidelines and new recommendations. In: U.S. Pharmacist. 2018 ; Vol. 43, No. 5. pp. 16-21.
@misc{64dd6a17785f4c32a676d70297ae806d,
title = "Cystic fibrosis: Update on treatment guidelines and new recommendations",
abstract = "Cystic fibrosis (CF) is a genetic disorder that affects various body systems, leading to premature death. Newborn screening in all states has helped identify those who have this disorder and allows for earlier interventions. Although traditionally viewed as a pulmonary disorder, treatments are available to address the various manifestations of CF. Airway clearance, nutritional support, pancreatic-enzyme replacement, and chronic antibiotic therapy are among the current recommended treatments. The most recent development involves the use of cystic fibrosis transmembrane conductance regulators that help to correct the underlying problem rather than just treat the symptoms. Pharmacists can serve an important role in the proper treatment of primary and secondary symptoms of CF.",
author = "DeSimone, {Edward M.} and Jennifer Tilleman and Giles, {Martin E.} and Boussina Moussa",
year = "2018",
month = "5",
day = "1",
language = "English (US)",
volume = "43",
pages = "16--21",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Cystic fibrosis

T2 - Update on treatment guidelines and new recommendations

AU - DeSimone, Edward M.

AU - Tilleman, Jennifer

AU - Giles, Martin E.

AU - Moussa, Boussina

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Cystic fibrosis (CF) is a genetic disorder that affects various body systems, leading to premature death. Newborn screening in all states has helped identify those who have this disorder and allows for earlier interventions. Although traditionally viewed as a pulmonary disorder, treatments are available to address the various manifestations of CF. Airway clearance, nutritional support, pancreatic-enzyme replacement, and chronic antibiotic therapy are among the current recommended treatments. The most recent development involves the use of cystic fibrosis transmembrane conductance regulators that help to correct the underlying problem rather than just treat the symptoms. Pharmacists can serve an important role in the proper treatment of primary and secondary symptoms of CF.

AB - Cystic fibrosis (CF) is a genetic disorder that affects various body systems, leading to premature death. Newborn screening in all states has helped identify those who have this disorder and allows for earlier interventions. Although traditionally viewed as a pulmonary disorder, treatments are available to address the various manifestations of CF. Airway clearance, nutritional support, pancreatic-enzyme replacement, and chronic antibiotic therapy are among the current recommended treatments. The most recent development involves the use of cystic fibrosis transmembrane conductance regulators that help to correct the underlying problem rather than just treat the symptoms. Pharmacists can serve an important role in the proper treatment of primary and secondary symptoms of CF.

UR - http://www.scopus.com/inward/record.url?scp=85048052466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048052466&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 16

EP - 21

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -